AbbVie’s MAVIRET Wins Positive CHMP Opinion, 96% Cure Rate for Acute Hepatitis C

Why It Matters

The CHMP’s positive opinion introduces a new, short‑duration regimen into a therapeutic area where treatment length and adherence have long been challenges. A 96% cure rate in acute hepatitis C could shift clinical practice toward earlier intervention, reducing the risk of chronic infection and its associated complications. For the European market, MAVIRET adds competitive pressure that may drive down prices, improve patient access, and accelerate progress toward hepatitis C elimination goals. Beyond patient outcomes, the approval would diversify AbbVie’s infectious‑disease revenue streams and reinforce its position against Gilead, the current market leader. The decision also underscores the EMA’s willingness to endorse novel indications for existing drug combinations, potentially encouraging other manufacturers to pursue acute‑infection indications for their HCV agents.

Key Takeaways

• CHMP issued a positive opinion for MAVIRET to treat acute hepatitis C in adults and children 3+ years old
• Phase 3 trial showed a 96% cure rate after an eight‑week regimen
• Approval decision expected in the EU in Q3 2026
• MAVIRET could compete with Gilead’s Harvoni/Epclusa and AbbVie’s own Mavyret
• AbbVie’s stock traded at $214, down 0.27% pre‑market

Pulse Analysis

AbbVie’s MAVIRET represents a strategic extension of its HCV franchise, leveraging the same active ingredients as Mavyret but targeting a distinct acute‑infection segment. The eight‑week course addresses a key barrier—treatment duration—that has historically limited uptake in acute cases, where patients may be less motivated to complete longer regimens. By achieving a 96% cure rate, MAVIRET not only meets efficacy benchmarks but also positions itself as a potential standard of care for early intervention, which could reduce the pool of chronic HCV patients over time.

From a market perspective, the entry of MAVIRET intensifies competition in a space where Gilead has long held pricing power. European payers, under pressure to meet WHO elimination targets, are likely to negotiate favorable pricing, especially given the drug’s shorter treatment window. AbbVie can capitalize on its existing supply chain and relationships with European health systems to accelerate market penetration, but it must also navigate the pricing expectations set by its own Mavyret and the broader competitive landscape.

Looking forward, the EMA’s final decision will be a bellwether for how regulators view acute‑infection indications for established drug combinations. A swift approval could encourage other firms to seek similar pathways, potentially reshaping the HCV treatment paradigm. For AbbVie, successful commercialization of MAVIRET could add a multi‑digit revenue stream by 2027, bolster its infectious‑disease portfolio, and provide a defensive bulwark against Gilead’s dominance, while also contributing to public‑health goals of hepatitis C eradication.